Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsFidelis Care oncology prior auth policy update | O…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentFidelis CarePolicy N/A

    Oncology medications and supportive agents prior authorization (Wellcare by Fidelis Care)

    Customize your policy alerts

    Sign up for all Fidelis Care policy alerts

    Know when Fidelis Care releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and review requirements for oncology medications and supportive agents for Medicare - Wellcare by Fidelis Care members, describing which drugs require review by Evolent and what providers must submit. It affects participating providers dispensing or administering oncology regimens in pharmacy, physician office, outpatient hospital, or ambulatory settings.

    Policy Summary
    PayerFidelis Care
    PolicyOncology medications and supportive agents prior authorization (Wellcare by Fidelis Care)
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateFeb 1, 2026
    Next Review DateN/A
    Key ActionSubmit the entire oncology regimen to Evolent for review via the Evolent web portal or phone; omissions may result in denial.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    100+HCPCS/Codes listed that require review
    Medical & PharmacyBenefit availability
    02/01/2026Effective date

    Coverage criteria and scope

    Prior review requirement

    Covered when ALL of the following are met

    Evolent review requirement: The specified oncology medications and supportive agents listed in this document require review by Evolent before being dispensed at a pharmacy or administered in a physician's office, outpatient hospital, or ambulatory setting for members of all ages.

    Includes drugs available via medical or pharmacy benefit; separate pharmacy-only list exists. Requests may be submitted via Evolent web portal or phone; non‑participating providers should submit to the plan via fax.

    Do NOT submit to Evolent for requests that are expressly listed as out-of-scope. Out-of-scope categories include: antibiotics; bone marrow, stem cell transplants, and CAR-T cell therapy; controlled substances (for example, morphine); equipment requests (such as infusion pumps); genetic laboratory testing and laboratory services; hemophilia drugs; inpatient drug requests; inpatient radiation and chemotherapy treatments; iron preparations; radiopharmaceuticals; surgeries/surgical procedures; sickle cell diagnoses and therapies; and immune globulins.

    HCPCS / J / Q codes requiring review

    Listed HCPCS/J/Q codes requiring reviewmixedCovered
    C9293GLUCARPIDASE
    C9307LINVOSELTAMAB-GCPT INJ
    C9308CARBOPLATIN (AVYXA) INJ
    J0185APREPITANT INJ
    J0207AMIFOSTINE INJ
    J0208SODIUM THIOSULFATE
    J0594BUSULFAN INJ
    J0641LEVOLEUCOVORIN INJ
    J0642LEVOLEUCOVORIN INJ
    J0870IMETELSTAT (RYTELO) / ELRANATAMAB-BCMM
    1–10 of 68
    1/7
    Policy Summary
    PayerFidelis Care
    PolicyOncology medications and supportive agents prior authorization (Wellcare by Fidelis Care)
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateFeb 1, 2026
    Next Review DateN/A
    Key ActionSubmit the entire oncology regimen to Evolent for review via the Evolent web portal or phone; omissions may result in denial.
    SourceLink
    On This Page
    Coverage criteria and scopeHCPCS / J / Q codes requiring reviewWhat providers must doSubmission and benefit assignment rulesWhere prior review appliesBiosimilar preferences and examplesOut-of-scope categories and definitionsBackground and purpose
    Pharmacy-benefit-only J-codes listedHCPCSCovered
    J7520SIROLIMUS ORAL
    J7527EVEROLIMUS ORAL
    J8501APREPITANT ORAL (various oral forms)
    J8530CYCLOPHOSPHAMIDE ORAL
    J8565GEFITINIB
    J8600MELPHALAN ORAL
    Oral agents aggregated under J8999 requiring review (pharmacy benefit)HCPCSCovered
    J8999Many oral oncology agents listed under J8999 (abemaciclib, abiraterone, alectinib, alpelisib, apalutamide, axitinib, brigatinib, capmatinib, ceritinib, crizotinib, dabrafenib, dasatinib, enzalutamide, erlotinib, ibrutinib, imatinib, lapatinib, lenalidomide, lorlatinib, nilotinib, osimertinib, palbociclib, pazopanib, ponatinib, ribociclib, ruxolitinib, sorafenib, sunitinib, vemurafenib, venetoclax, many others as listed in source chunks 15-18)

    What providers must do

    Prior Authorization

    Evolent review required

    Oncology medications and supportive agents listed by HCPCS/J- and Q-codes require review by Evolent prior to dispensing or administration. This applies to participating providers for drugs administered in physician offices, outpatient hospitals, ambulatory settings, and pharmacy-dispensed agents for members of all ages. Clinical trial medications may also be submitted for review.

    • Submit requests via Evolent Web portal: my.newcenturyhealth.com
    • Phone: 1-888-999-7713, option 1
    • Non-participating providers: submit to the plan via fax 1-844-235-5090 (formerly 1-877-882-5892)
    Note

    Biosimilar preference note

    Preferred biosimilar agents are listed for certain oncology-related classes; however, providers should still send the preferred agent(s) to Evolent for review. Providing the preferred biosimilar does not replace the requirement to submit the complete regimen.

    • Erythropoiesis-stimulating agents: Medical benefit — Retacrit (if unavailable due to shortage: Epogen); Pharmacy benefit — Procrit
    • Trastuzumab: Medical benefit — Trazimera; Pharmacy benefit — Herceptin, Herceptin Hylecta, Herzuma, Kanjinti, Ogivri, Ontruzant, Trazimera
    • Bevacizumab: Medical benefit — Mvasi, Zirabev; Pharmacy benefit — Avastin, Mvasi, Zirabev
    • Hematopoietic agents: Medical & Pharmacy benefit — Zarxio
    • Rituximab: Medical benefit — Ruxience, Truxima; Pharmacy benefit — Riabni, Rituxan, Rituxan Hycela, Ruxience, Truxima
    • Bone agents and other supportive agents: listed in provider materials (e.g., zoledronic acid, pamidronate, Prolia, Xgeva)
    Denial Risk

    Complete regimen submission required

    Submit the entire oncology regimen to Evolent for review — do NOT omit any component (including supportive agents, biosimilars, antiemetics, growth factors, or administration codes). Omitting any part of the regimen when submitting may result in a denial.

    • Submit the full regimen regardless of prior authorization requirement
    • Include all medical and pharmacy benefit agents and relevant HCPCS/J-codes
    • Use Evolent web portal or phone for participating providers; non-participating providers to submit to the plan via fax 1-844-235-5090
    Documentation Required

    Where and how to submit

    Where and how to submit: participating providers must submit requests to Evolent via the web portal (my.newcenturyhealth.com) or by phone (1-888-999-7713, option 1). Non-participating providers must submit to the plan (fax 1-844-235-5090). Include the entire regimen and all supporting documentation to facilitate review.

    • Evolent Web portal: my.newcenturyhealth.com
    • Evolent phone: 1-888-999-7713, option 1
    • Plan fax for non-participating providers: 1-844-235-5090 (new as of 10/1/2023)
    • Clinical trials may be submitted to Evolent for review

    Submission and benefit assignment rules

    Preferred agents and benefit assignment

    Submission requirement

    Submit regimen: Submit the entire oncology regimen to Evolent regardless of whether individual agents are preferred or require medical vs pharmacy benefit determination.

    Omitting any part of the regimen when submitting to Evolent may result in a denial.

    Preferred agents: Preferred biosimilar or benefit‑specific agents (e.g., Retacrit for medical benefit; Procrit for pharmacy benefit; Trazimera preferred for trastuzumab on the medical benefit; Mvasi/Zirabev preferred bevacizumab biosimilars) should be sent to Evolent for review.

    Preferred agent lists do not eliminate the requirement to submit for review; some agents may be available via either medical or pharmacy benefit.

    Where prior review applies

    Prior Authorization

    Site-of-care review requirement

    Drugs on the listed HCPCS/J/Q code tables require Evolent review before they are dispensed at a pharmacy or administered in a physician office, outpatient hospital, or ambulatory setting.

    Biosimilar preferences and examples

    Billing Rule

    Epogen/Procrit — preferred biosimilar guidance

    For erythropoiesis‑stimulating agents the preferred biosimilar for the medical benefit is Retacrit (Epogen may be used if Retacrit is unavailable due to shortage); Procrit is listed for the pharmacy benefit. Preferred agents must still be submitted to Evolent for review.

    Billing Rule

    Trastuzumab — Trazimera preferred (medical); multiple pharmacy options

    For trastuzumab, Trazimera is listed as the preferred agent for the medical benefit; multiple trastuzumab products (Herceptin, Herceptin Hylecta, Herzuma, Kanjinti, Ogivri, Ontruzant, Trazimera) are listed for the pharmacy benefit — submit for Evolent review.

    Billing Rule

    Bevacizumab — preferred biosimilars listed

    For bevacizumab, Mvasi and Zirabev are listed as preferred for the medical benefit; the pharmacy benefit includes Avastin and biosimilars (Mvasi, Zirabev). Submit the chosen agent to Evolent for review.

    Out-of-scope categories and definitions

    Out of scope with Evolent
    Out-of-scope categories — submit to Evolent?Do NOT submit requests in the following categories to Evolent: Antibiotics; Bone marrow, stem cell transplants and CAR‑T cell therapy; Controlled substances (e.g., morphine); Equipment requests (infusion pumps); Genetic lab testing and laboratory services; Hemophilia drugs; Inpatient drug requests; Inpatient radiation and chemotherapy treatments; Iron preparations; Radiopharmaceuticals; Surgeries/surgical procedures; Sickle cell diagnoses and therapies; Immune globulins.
    Preferred biosimilars — submit for reviewPreferred biosimilar agents are listed (see policy) but providers should still send preferred agents to Evolent for review.
    Erythropoiesis‑stimulating agents preferenceMedical benefit: Retacrit (if unavailable due to shortage: Epogen); Pharmacy benefit: Procrit.
    Trastuzumab preferenceMedical benefit: Trazimera; Pharmacy benefit: Herceptin, Herceptin Hylecta, Herzuma, Kanjinti, Ogivri, Ontruzant, Trazimera.
    Bevacizumab preferenceMedical benefit: Mvasi, Zirabev; Pharmacy benefit: Avastin, Mvasi, Zirabev.

    Background and purpose

    This document lists oncology and supportive care drugs that require prior review by Evolent to establish use for a medically accepted indication. Providers must submit the entire oncology regimen to Evolent for review; omitting any part of the regimen may result in a denial. The list includes agents across medical and pharmacy benefits and identifies preferred biosimilar agents for some classes, but preferred agents still require submission to Evolent for review.